相关实验视频

Updated: Jun 29, 2025

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

配备基于IL-2的融合蛋白,可以改善CAR-T细胞的适应性和对固体瘤的疗效

Sijin Li¹, Yifei Xia¹, Rui Hou²

¹Cancer Institute, Xuzhou Medical University, China; Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, China; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, China.

Biochimica et biophysica acta. Molecular basis of disease

|April 7, 2024

概括

改造的仿真抗原受体T (CAR-T) 细胞共表达突变的互白素-2 (IL-2m) 显示出增强的适应性和透在固体瘤中. 这一策略改善了瘤控制,克服了免疫抑制障碍,为固体瘤免疫治疗提供了一种有前途的方法.

科学领域:

免疫治疗是一种免疫疗法.
细胞疗法细胞疗法
在瘤学瘤学.

背景情况:

化学抗原受体T (CAR-T) 细胞疗法在血液癌症中取得了成功,但由于免疫抑制性瘤微环境,在固体瘤中有效性有限.
克服这些免疫抑制障碍对于推进对固体瘤的CAR-T细胞治疗至关重要.

研究的目的:

设计具有针对和抑制固体瘤的增强能力的CAR-T细胞.
开发一种通用的CAR-T细胞武装策略,以改善固体瘤治疗.

主要方法:

CAR-T细胞被设计为共同表达瘤抗原向的CAR和一个突变的人类介质素-2 (IL-2m).
进行了体外和体外评估,以评估CAR-T细胞适应性,瘤微环境调节,瘤透和整体瘤控制.

主要成果:

经过工程设计的CAR-T细胞在体外表现出增强的适应性.
协同表达IL-2m重塑了免疫排除的瘤微环境,并改善了CAR-T细胞透到固体瘤中的情况.
在没有显著的全身毒性的情况下实现了显著的瘤控制.

结论:

与IL-2突变蛋白共同设计CAR-T细胞是一种有效的策略,可以增强它们的抗固体瘤活性.
这种方法表明,通过克服免疫抑制瘤微环境,在固体瘤中优化CAR-T细胞治疗的潜力.

关键词:

采用细胞免疫疗法采用细胞免疫疗法细胞工程是细胞工程.细胞因子细胞因子一个T细胞细胞.瘤微环境是一个微环境.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

A Spheroid Killing Assay by CAR T Cells

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...